A Multicenter, Multinational Extension of Study PRV-031-001 to Evaluate the Long-Term Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adolescents With Recent-Onset Type 1 Diabetes Mellitus
Latest Information Update: 03 Oct 2024
At a glance
- Drugs Teplizumab (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Acronyms PROTECT Extension
- Sponsors Provention Bio
- 05 Jan 2024 Planned End Date changed from 1 Jun 2026 to 1 Nov 2026.
- 05 Jan 2024 Planned primary completion date changed from 1 Jun 2026 to 1 Nov 2026.
- 05 Jan 2024 Status changed from recruiting to active, no longer recruiting.